Peptide Therapeutics for Autoimmune and Bone Disease

The patent employs parameter changes by modifying the chemical structure of peptide sequences to create compounds with improved therapeutic profiles. Specifically, the invention uses peptides with specific amino acid sequences (Formula 1: (X1-X2-X3)n where X1=arginine/histidine/lysine, X2=aspartic acid/glutamic acid, X3=glycine/alanine/valine/methionine/isoleucine/leucine, n=1-10) that selectively inhibit Th17 cell differentiation and IL-6 secretion without the harmful side effects of conventional treatments. This structural parameter optimization resolves the contradiction between therapeutic effectiveness and side effect profile.

The patent applies the copying principle by designing synthetic peptides that mimic or interfere with natural biological sequences involved in Th17 cell differentiation and IL-6 production. The peptide compounds replicate key functional motifs to achieve selective inhibition of pathological processes while sparing normal physiological functions, thereby providing effective treatment without significant side effects.

The patent applies local quality by designing peptides with specific amino acid compositions and sequences that confer selective activity against Th17 cell differentiation and IL-6 secretion pathways. The localized chemical properties of specific amino acid residues in the peptide sequence enable precise interaction with target molecules in these pathways, achieving high target specificity and effective inhibition simultaneously.

The patent uses segmentation by dividing the therapeutic function into specific peptide sequences that can independently target different aspects of the Th17/IL-6 pathway. The modular peptide structure ((X1-X2-X3)n) allows for targeted intervention at specific points in the pathological process, achieving both specificity and effectiveness through segmented functional domains.